By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Researchers surveyed survivors of early-stage hormone receptor-positive breast cancer who did not receive chemotherapy to assess the symptom burden in this patient population.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

Prospective study on abemaciclib-induced interstitial lung disease in metastatic breast cancer reveals a 7.4% incidence rate.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...